Withania coagulans

Withania coagulans is a shrub from the Solanaceae family containing withanolides as primary bioactive compounds that modulate glucose metabolism and cellular apoptosis pathways. The plant extract demonstrates anti-diabetic effects by enhancing insulin sensitivity and shows anti-proliferative activity against prostate cells.

Origin & History

Withania coagulans is a plant native to the Salt Range of Pakistan and arid regions of South Asia, belonging to the nightshade (Solanaceae) family. Its fruit, leaf stalk, root, and leaves are processed into aqueous and methanolic extracts, standardized based on phenolic compounds and flavonoid content.

Historical & Cultural Context

Withania coagulans has ethnopharmacological use in South Asian traditional medicine. In Ayurvedic medicine, it is known as Rishyagandha and traditionally used for Prameha, a classification encompassing metabolic disorders.

Health Benefits

• May reduce benign prostatic hyperplasia symptoms by decreasing prostatic index and inducing cell apoptosis (animal studies only, PubMed 27878112)
• Shows potential for blood sugar control with 52.9-54.1% reductions in fasting and post-meal glucose levels (diabetic rat studies, PubMed 25295146)
• Demonstrates uric acid-lowering effects through xanthine oxidase inhibition and enhanced excretion (mouse studies, PubMed 40712280)
• Exhibits gastric protective properties comparable to H2 receptor antagonists at 10 mg/kg (rat studies, PubMed 40636368)
• Contains compounds with anticancer activity showing 2-4x higher potency than methotrexate in vitro (cell culture studies, PubMed PMC6026361)

How It Works

Withania coagulans works primarily through its withanolide compounds, which enhance insulin sensitivity and glucose uptake in peripheral tissues. The extract modulates apoptotic pathways by activating caspase enzymes and reducing Bcl-2 expression in prostate cells. Its anti-diabetic effects involve improved pancreatic beta-cell function and enhanced glucose transporter activity.

Scientific Research

Current evidence consists entirely of animal models and in vitro studies, with no human clinical trials identified. Key studies include rat models for BPH (PubMed 27878112), diabetic kidney protection (PubMed 25295146), and gastric ulcer prevention (PubMed 40636368), plus mouse models for hyperuricemia (PubMed 40712280).

Clinical Summary

Current evidence is limited to animal studies with no human clinical trials available. In diabetic rat models, withania coagulans extract reduced fasting glucose by 52.9% and post-meal glucose by 54.1% over 4 weeks. Prostate studies in rats showed reduced prostatic index and increased apoptosis markers, but sample sizes were small (n=6-8 per group). Human efficacy and safety data are lacking.

Nutritional Profile

Withania coagulans (Indian rennet/paneer doda) is a medicinal plant whose fruits and seeds are primarily used therapeutically rather than as a staple food, so conventional macronutrient data is limited. Seeds contain approximately 15-20% protein (rich in essential amino acids), 20-25% fixed oils/lipids (including linoleic, oleic, and stearic acids), and 30-40% carbohydrates with notable dietary fiber content. Ash content approximately 5-8%. Key bioactive compounds include: withanolides (steroidal lactones, primarily withacoagulin A-K at ~0.1-0.5% dry weight), which are principal pharmacologically active constituents; coagulin-series compounds (coagulin A, B, C, L at trace concentrations); alkaloids including withanine, somniferine, and tropine (~0.2-0.4% alkaloid content); flavonoids and polyphenols (quercetin, kaempferol derivatives); saponins (~2-5% dry weight); phytosterols including beta-sitosterol and stigmasterol; and volatile oils (~0.1%). Micronutrients include iron, zinc, calcium, magnesium, and potassium, though precise concentrations are not well-characterized in the literature. Bioavailability notes: withanolides are lipophilic and absorption may be enhanced with dietary fat co-consumption; traditional aqueous decoctions likely yield lower bioavailability of fat-soluble constituents compared to ethanolic extracts; first-pass metabolism may significantly reduce systemic bioavailability of some alkaloids. The xanthine oxidase-inhibiting activity (relevant to uric acid reduction) is attributed primarily to flavonoid and polyphenol fractions.

Preparation & Dosage

Animal studies have used: 200 mg/kg for hyperuricemia, 10 mg/kg fruit extract for gastric protection. No human dosage recommendations can be established from available evidence. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Ashwagandha, Saw Palmetto, Alpha-Lipoic Acid, Milk Thistle, Gymnema Sylvestre

Safety & Interactions

Safety data in humans is insufficient due to lack of clinical trials. Traditional use suggests general tolerability, but potential side effects remain unknown. No documented drug interactions exist, though theoretical interactions with diabetes medications and anticoagulants are possible. Pregnancy and breastfeeding safety is undetermined, so use should be avoided during these periods.